Tango Therapeutics exec trades 27,000 shares

Tango Therapeutics President of R&D Crystal Adam exercised stock options for 27,000 shares of common stock at an exercise price of $5.20 per share and, on the same day, sold 27,000 shares at a weighted-average price of $21.2029 per share.

Rhea-AI Filing Summary

Tango Therapeutics President of R&D Crystal Adam exercised stock options for 27,000 shares of common stock at an exercise price of $5.20 per share and, on the same day, sold 27,000 shares at a weighted-average price of $21.2029 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan. After the sale, Adam directly holds 112,622 shares of Tango Therapeutics common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 27,000 shares ($432K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Crystal Adam

Role President, R&D

Sold 27,000 shs ($572K)

Approx. gross sale proceeds $572K

Approx. exercise cost $140K

Approx. pre-tax spread $432K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	27,000	$0.00	$0.00
Exercise	Common Stock	27,000	$5.20	$140K
Sale	Common Stock	27,000	$21.2029	$572K

Holdings After Transaction: Stock Option (Right to Buy) — 433,500 contracts (Direct); Common Stock — 112,622 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
2. F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
3. F3. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Key Figures

Options exercised: 27,000 shares Exercise price: $5.20 per share Shares sold: 27,000 shares +3 more

6 metrics

Options exercised 27,000 shares Stock option (right to buy) exercised on April 1, 2026

Exercise price $5.20 per share Strike price for 27,000 options exercised

Shares sold 27,000 shares Open-market sale of common stock on April 1, 2026

Weighted-average sale price $21.2029 per share Sales executed between $21.00 and $21.69

Shares held after sale 112,622 shares Direct common stock ownership after transactions

Options balance reported 433,500 options Total stock options shown following derivative transaction

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy, weighted-average price, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy financial

"security_title: "Stock Option (Right to Buy)" for 27,000 underlying shares of common stock."

weighted-average price financial

"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.69, inclusive."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

open-market sale financial

"transaction_action: "open-market sale" for 27,000 shares of common stock."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

vesting in 36 equal monthly installments financial

"remaining option shares vesting in 36 equal monthly installments thereafter."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tango Therapeutics (TNGX) executive Crystal Adam report in this Form 4?

Crystal Adam, President of R&D at Tango Therapeutics, reported exercising options for 27,000 shares at $5.20 and selling 27,000 shares at a weighted-average price of $21.2029, all on the same date under a Rule 10b5-1 trading plan.

How many Tango Therapeutics (TNGX) shares did Crystal Adam sell and at what price?

Crystal Adam sold 27,000 shares of Tango Therapeutics common stock at a weighted-average price of $21.2029 per share, in multiple transactions within a price range from $21.00 to $21.69, as disclosed in the Form 4 footnote.

What stock options did Crystal Adam exercise in Tango Therapeutics (TNGX)?

She exercised a stock option (right to buy) covering 27,000 underlying shares of Tango Therapeutics common stock at an exercise price of $5.20 per share, with the option originally scheduled to vest over four years and expiring on March 1, 2033.

How many Tango Therapeutics (TNGX) shares does Crystal Adam hold after these transactions?

Following the reported exercise and sale, Crystal Adam directly holds 112,622 shares of Tango Therapeutics common stock. The Form 4 shows this as her post-transaction direct ownership balance in the non-derivative securities table.

Were Crystal Adam’s Tango Therapeutics (TNGX) trades made under a Rule 10b5-1 plan?

Yes. The Form 4 states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025, indicating they were pre-arranged rather than timed at her sole discretion.

What vesting schedule applied to Crystal Adam’s Tango Therapeutics (TNGX) stock option?

The option vests over four years: 25% vested on February 27, 2024, with the remaining shares vesting in 36 equal monthly installments thereafter, as described in the Form 4 footnote detailing the award’s vesting terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 08:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crystal Adam

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.,

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		M(1)		27,000	A	$5.2	139,622	D
Common Stock	04/01/2026		S(1)		27,000	D	$21.2029(2)	112,622	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.2	04/01/2026		M(1)			27,000	(3)	03/01/2033	Common Stock	27,000	$0	433,500	D

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.00 to $21.69, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.

	/s/ Julie Fogarty, as attorney-in-fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)